Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cameron

Showing results (81-90 of 134) with videos related to

Pageof 14
Sort By:
Breast Cancer Research and Treatment|March 29, 2013
Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancerJohn M S Bartlett, Roger A'hern, Tammy Piper, et al.
Histopathology|October 23, 2009
Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-upJeremy St J Thomas, Gillian R Kerr, Wilma J L Jack, et al.
Advances in Therapy|March 13, 2019
Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical StudiesJ Michael Dixon, David A Cameron, Laura M Arthur, et al.
The Lancet. Oncology|August 10, 2024
Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trialLinda J Williams, Ian H Kunkler, Karen J Taylor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapyJohn M S Bartlett, Ian O Ellis, Mitch Dowsett, et al.
The Journal of Pathology|March 21, 2012
Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progressionMelanie Spears, Carrie A Cunningham, Karen J Taylor, et al.
The Journal of Pathology|November 16, 2012
Authors' replyMelanie Spears, Carrie A Cunningham, Karen J Taylor, et al.
British Journal of Cancer|November 23, 2016
Trastuzumab-associated cardiac events in the Persephone trialHelena M Earl, Anne-Laure Vallier, Janet Dunn, et al.
Breast Cancer Research and Treatment|November 23, 2017
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trialJoyce O'Shaughnessy, Katarina Petrakova, Gabe S Sonke, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2023
EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomyMarjanka K Schmidt, Jennifer E Kelly, Anne Brédart, et al.
Pageof 14

Showing results (81-90 of 134) with videos related to

Sort By:
Pageof 14
Breast Cancer Research and Treatment|March 29, 2013
Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancerJohn M S Bartlett, Roger A'hern, Tammy Piper, et al.
Histopathology|October 23, 2009
Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-upJeremy St J Thomas, Gillian R Kerr, Wilma J L Jack, et al.
Advances in Therapy|March 13, 2019
Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical StudiesJ Michael Dixon, David A Cameron, Laura M Arthur, et al.
The Lancet. Oncology|August 10, 2024
Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trialLinda J Williams, Ian H Kunkler, Karen J Taylor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapyJohn M S Bartlett, Ian O Ellis, Mitch Dowsett, et al.
The Journal of Pathology|March 21, 2012
Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progressionMelanie Spears, Carrie A Cunningham, Karen J Taylor, et al.
The Journal of Pathology|November 16, 2012
Authors' replyMelanie Spears, Carrie A Cunningham, Karen J Taylor, et al.
British Journal of Cancer|November 23, 2016
Trastuzumab-associated cardiac events in the Persephone trialHelena M Earl, Anne-Laure Vallier, Janet Dunn, et al.
Breast Cancer Research and Treatment|November 23, 2017
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trialJoyce O'Shaughnessy, Katarina Petrakova, Gabe S Sonke, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2023
EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomyMarjanka K Schmidt, Jennifer E Kelly, Anne Brédart, et al.
Pageof 14